The Cost-Effectiveness Of The Manchester ‘Lung Health Checks’, A Community-Based Lung Cancer Low-Dose CT Screening Pilot

In recent years the debate over the value of screening for lung cancer has intensified with the conclusion of a number of high cost randomised trials from around the world, including NLST, UKLS, and NELSON [1 –3]. Based largely on the results of NLST the US Preventive Services Task Force (USPSTF) recommended screening with LDCT in 2013 [4]. This has been followed by similar statements from other countries including the Chief Executive of the NHS in the UK, Simon Stevens, in 2017 [5] and the recent Euro pean position statement [6].

Source: Lung Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Sebastian Hinde, Tessa Crilly, Haval Balata, Rachel Bartlett, John Crilly, Phil Barber, Anthony Threlfall, Janet Tonge, Richard Booton, Phil Crosbie Source Type: research